Europe Epilepsy Market Forecast to 2030 - Regional Analysis - by Type (Progressive Myoclonic Epilepsy, Reflex Epilepsy, Generalized Epilepsy, and Other), Route of Administration (Oral, Parenteral, and Others), Treatment Type (First Generation Drugs, Second Generation Drugs, and Third Generation Drugs), Age Group (Adult and Children), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)
The Europe epilepsy market was valued at US$ 1,940.58 million in 2022 and is expected to reach US$ 2,626.05 million by 2030; it is estimated to register a CAGR of 3.9% from 2022 to 2030.
Increasing Investments in Development of Epilepsy Therapies Drive Europe Epilepsy Market
The healthcare sector is transforming with rapid technological developments and innovation, enhancing healthcare services and quality of care. The epilepsy market is characterized by the presence of several small and large companies and organizations implementing various growth strategies. The availability of funding enables companies and organizations to boost production levels, expand into new markets, invest in new/improved technologies, and allocate more resources to R&D. A few of the notable investments in the epilepsy market, contributing to the market progress, have been mentioned below.
• In March 2023, the Swedish government decided to commission Vinnova, Sweden’s innovation agency, a total of US$ 7.7 million (80 million SEK) to establish a national innovation cluster for commercialization, skills development, and production capacity build-up for cell therapies and other advanced treatments such as gene therapy.
• In November 2022, Scientists at Aston University in the UK, working on a project to develop new drug treatments to prevent the beginning of childhood epilepsy, were awarded US$ 2.4 million (£2 million) to discover the disease mechanism in the brain and the ways of epilepsy prevention. This three-year project funded by the Medical Research Council is a collaboration led by researchers in the College of Health and Life Sciences at Aston University, combined with Bristol University and Jazz Pharmaceuticals.
• In July 2022, Cerebral Therapeutics secured US$ 40 million in the Series C round funding to get its implanted infusion epilepsy treatment ready for phase 3 development. The funding round was led by Lynx1 Capital Management among other investors, including RA Capital Management and Perceptive Advisors. Cerebral Therapeutics intends to deliver the specified levels of valproate to the central nervous system without causing weight gain, which was witnessed in subjects of oral formulation studies.
• In November 2021, Neurava, a startup located in Indiana, received over US$ 0.65 million in seed funding led by Elevate Ventures with participation from Purdue Foundry, UCB Biopharma, First Leaf Capital, iO Life Ventures, and angel investors. The company is working on the development of a wearable device to monitor and alert users about the approaching risk of sudden, unexpected death caused by epilepsy.
• In June 2021, Neurona Therapeutics Inc., a biotherapeutics company, successfully completed a US$ 41.5 million financing to advance the company’s pipeline of wholly owned, off-the-shelf cell therapies for various indications, including NRTX-1001 (a Phase 1/2a clinical study), an inhibitory neuronal cell therapy for the treatment of chronic focal epilepsy.
Therefore, increasing investments in the development of advanced treatments propels the growth of the epilepsy market.
Europe Epilepsy Market Overview
The European epilepsy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the epilepsy market. The European epilepsy market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, approvals of new drugs by regulatory authorities, increase in funding by governments to improve and develop effective drugs and treatments for seizures in the region.
Europe Epilepsy Market Revenue and Forecast to 2030 (US$ Million)
Europe Epilepsy Market Segmentation
The Europe epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.
Based on type, the Europe epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.
In terms of route of administration, the Europe epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.
By treatment type, the Europe epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.
Based on age group, the Europe epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.
In terms of distribution channel, the Europe epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.
By country, the Europe epilepsy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe epilepsy market share in 2022.
Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Europe epilepsy market.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. Europe Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - Europe Analysis
6.1 Europe: Epilepsy Market
7. Europe Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. Europe Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. Europe Epilepsy Market - Country Analysis
12.1 Europe: Epilepsy Market Overview
12.1.1 Europe: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 United Kingdom: Epilepsy Market Overview
12.1.1.2 United Kingdom: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
12.1.1.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 Germany: Epilepsy Market Overview
12.1.1.4 Germany: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 Germany: Epilepsy Market Breakdown, by Type
12.1.1.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 Germany: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 France: Epilepsy Market Overview
12.1.1.6 France: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 France: Epilepsy Market Breakdown, by Type
12.1.1.6.2 France: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 France: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 France: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.7 Spain: Epilepsy Market Overview
12.1.1.8 Spain: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.8.1 Spain: Epilepsy Market Breakdown, by Type
12.1.1.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
12.1.1.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
12.1.1.8.4 Spain: Epilepsy Market Breakdown, by Age Group
12.1.1.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.9 Italy: Epilepsy Market Overview
12.1.1.10 Italy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.10.1 Italy: Epilepsy Market Breakdown, by Type
12.1.1.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
12.1.1.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
12.1.1.10.4 Italy: Epilepsy Market Breakdown, by Age Group
12.1.1.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.11 Rest of Europe: Epilepsy Market Overview
12.1.1.12 Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
12.1.1.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
12.1.1.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
12.1.1.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
12.1.1.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 CombiGene AB
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 LivaNova Plc
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Novartis AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Medtronic Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 GSK Plc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 H. Lundbeck AS
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
List of Tables
Table 1. Europe Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
Table 11. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 12. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 13. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 14. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 15. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 17. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 19. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 20. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 21. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 23. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 24. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 25. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 26. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 27. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 28. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 29. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 32. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 33. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 34. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 35. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 36. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 37. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 38. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 39. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 40. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 41. Recent Organic Growth Strategies in Epilepsy Market
Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market
List of Figures
Figure 1. Europe Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Europe: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in Epilepsy Market
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- CombiGene AB
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.